"ADAM Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of membrane-anchored glycoproteins that contain a disintegrin and metalloprotease domain. They are responsible for the proteolytic cleavage of many transmembrane proteins and the release of their extracellular domain.
| Descriptor ID |
D051722
|
| MeSH Number(s) |
D08.811.277.656.675.374.102 D09.400.430.500 D12.776.395.033
|
| Concept/Terms |
ADAM Proteins- ADAM Proteins
- A Disintegrin and Metalloprotease Proteins
- ADAM (A Disintegrin and Metalloprotease) Proteins
|
Below are MeSH descriptors whose meaning is more general than "ADAM Proteins".
Below are MeSH descriptors whose meaning is more specific than "ADAM Proteins".
This graph shows the total number of publications written about "ADAM Proteins" by people in this website by year, and whether "ADAM Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 6 | 2 | 8 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 1 | 5 |
| 2010 | 1 | 0 | 1 |
| 2011 | 4 | 1 | 5 |
| 2012 | 0 | 4 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 4 | 0 | 4 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ADAM Proteins" by people in Profiles.
-
Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13. Haemophilia. 2023 Nov; 29(6):1638-1645.
-
Elevated inflammatory gene expression in intervertebral disc tissues in mice with ADAM8 inactivated. Sci Rep. 2021 01 19; 11(1):1804.
-
The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):130-134.
-
Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sj?gren's syndrome. Ann Rheum Dis. 2017 Aug; 76(8):1458-1466.
-
Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. Osteoarthritis Cartilage. 2016 Feb; 24(2):299-306.
-
Activation of peroxisome proliferator-activated receptor a stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8445-50.
-
Deletion of ADAMTS5 does not affect aggrecan or versican degradation but promotes glucose uptake and proteoglycan synthesis in murine adipose derived stromal cells. Matrix Biol. 2015 Sep; 47:66-84.
-
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015 Aug; 23(8):1254-66.
-
MicroRNA-146a reduces IL-1 dependent inflammatory responses in the intervertebral disc. Gene. 2015 Jan 25; 555(2):80-7.
-
Fibronectin fragments and the cleaving enzyme ADAM-8 in the degenerative human intervertebral disc. Spine (Phila Pa 1976). 2014 Jul 15; 39(16):1274-9.